Enoxaparin Study for COVID-19 and Influenza
COVID-19 Coagulopathy Extension Study
Recruiting
Observational Study
COVID-19
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 99
- Sex
- Any
- Study type
- Observational
- Participants needed
- 180 (estimated)
- Sponsor
- University of Iowa · Other
Who this trial is looking for
This trial is looking for hospitalized adults with COVID-19 or influenza. Participants will provide blood samples to help researchers understand blood clotting issues related to these infections.
Are You a Good Fit for This Trial?
You may be able to join if
- I am at least 18 years old
- I have been hospitalized for COVID-19 symptoms
- I have a confirmed COVID-19 infection by test within the last 4 weeks
- I have been hospitalized for reasons unrelated to COVID-19 but have a positive COVID-19 test
- I have been hospitalized for influenza symptoms
- I have a confirmed influenza infection by test within the last 4 weeks
- I have tested negative for COVID-19
You may not be able to join if
- I am currently pregnant
- I am a prisoner
- I have a history of a bleeding disorder
- I have active cancer
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
At the University of Iowa, the investigators led a multicenter randomized clinical trial comparing standard prophylactic dose to intermediate dose enoxaparin in hospitalized patients with COVID-19 (NCT04360824). As part of an exploratory biomarker component of this trial, blood samples were collected from hospitalized COVID-19 patients at enrollment and weekly for up to 30 days of hospitalization.…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion criteria
Subjects must meet all inclusion criteria in one of the following three categories:
1. Acute COVID-19
* Hospital admission for management of symptoms related to COVID-19
* Laboratory confirmed infection with SARS-CoV-2 by either PCR or antigen testing within 4 weeks of ho…
Contacts